| Lan, Jianping |
NCT04547049: A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies |
|
|
| Recruiting | 3 | 160 | RoW | Cytarabine, Busulfan, Cyclophosphamide, Me-CCNU, Rabbit antithymocyte globulin, Allogeneic HSCT, Cyclosporin A, Mycophenolate Mofetil, MTX | First Affiliated Hospital of Zhejiang University | Leukemia | 09/25 | 12/25 | | |
NCT05084027: Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT |
|
|
| Recruiting | 2 | 50 | RoW | venetoclax combining with fludarabine and melphalan | First Affiliated Hospital of Zhejiang University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial People's Hospital, The affiliated people's hospital of Ningbo University, First Affiliated Hospital of Wenzhou Medical University, Ningbo Hospital of Zhejiang University, The First Affiliated Hospital of Zhejiang Chinese Medical University | Hematologic Malignancy, Older Patients, Allogeneic Hematopoietic Stem Cell Transplantation | 09/22 | 09/24 | | |
NCT04803929: Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5) |
|
|
| Recruiting | 1 | 25 | RoW | anti-ILT3 CAR-T | Carbiogene Therapeutics Co. Ltd., Zhejiang Provincial People's Hospital | AML M4, AML M5 | 03/24 | 03/26 | | |
NCT05376345: BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 32 | RoW | LCAR-BCDR cells product | Weijun Fu, Nanjing Legend Biotech Co. | Relapsed/Refractory Multiple Myeloma | 06/24 | 09/26 | | |
NCT05355675: The Association of Microbiota Composition With cGVHD After Allo-HSCT |
|
|
| Recruiting | N/A | 300 | RoW | blood sample, stool sample | First Affiliated Hospital of Zhejiang University | Hematopoietic Stem Cell Transplantation, Hematologic Malignancy, Chronic Graft-versus-host-disease, Complication | 05/25 | 05/25 | | |
| Jin, Lai |
NCT04803929: Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5) |
|
|
| Recruiting | 1 | 25 | RoW | anti-ILT3 CAR-T | Carbiogene Therapeutics Co. Ltd., Zhejiang Provincial People's Hospital | AML M4, AML M5 | 03/24 | 03/26 | | |
